(Part 1 of 6) Substance Use Disorder (SUD) 101: Why Should We Care About SUD in Patients With HIV?

Assessment of Needs

Drug Enforcement Agency certificate holders will be required to complete 8 hours of training on opioids, substance use disorders (SUDs), and pain management as of June 27, 2023. The IAS–USA is excited to support you in meeting these new requirements with a free, 6-part webinar series comprising 8 hours of training to help you provide the best possible care for your HIV patients! The first webinar in the series, led by Sandra Springer, MD, and moderated by Ellen F. Eaton, MD, examines the epidemiology of SUD and helps clinicians understand the challenges in treating HIV patients with SUD.

Learning Objectives

 Upon completion of this activity, learners will be able to: 

• Explain the epidemiology of substance use and its impact on HIV treatment
• Understand the “why” behind mastering the basics of substance use of disorder treatment
• Screen for substance use disorders in HIV prevention and treatment settings

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on Tuesday, August 22, 2023, 10:30 AM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.

Presenter

Dr Springer reported receiving consulting fees from Alkermes, Inc, and receiving in-kind study drug donations from Alkermes, Inc, and Indivior, Inc. (Updated August 10, 2023)

Moderator

Dr Eaton reported receiving grants paid to her institution from Bristol Myers Squibb Co and receiving consulting fees from Gilead Sciences. (Updated August 10, 2023)

COW Board

The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/